[HTML] nih.gov

[HTML][HTML] CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)

S Motas, V Haurigot, M Garcia, S Marcó, A Ribera… - JCI insight, 2016 - ncbi.nlm.nih.gov
Mucopolysaccharidosis type II (MPSII) is an X-linked lysosomal storage disease
characterized by severe neurologic and somatic disease caused by deficiency of iduronate …
被引用次数：89 相关文章
[PDF] ump.edu.pl

[PDF][PDF] CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)

S Motas, V Haurigot, M Garcia, S Marcó, A Ribera… - zfk.ump.edu.pl
Mucopolysaccharidosis type II (MPSII), or Hunter syndrome, is an X-linked recessive
lysosomal storage disease (LSD) caused by deficiency of iduronate-2-sulfatase (IDS)(1, 2) …

CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome).

S Motas, V Haurigot, M Garcia, S Marcó, A Ribera… - JCI Insight, 2016 - europepmc.org
Mucopolysaccharidosis type II (MPSII) is an X-linked lysosomal storage disease
characterized by severe neurologic and somatic disease caused by deficiency of iduronate …

[引用][C] CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)

S Motas, V Haurigot, M Garcia, S Marcó, A Ribera… - JCI Insight, 2016 - cir.nii.ac.jp
CNS-directed gene therapy for the treatment of neurologic and somatic
mucopolysaccharidosis type II (Hunter syndrome) | CiNii Research CiNii 国立情報学研究所 …
[PDF] researchgate.net

[PDF][PDF] CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)

S Motas, V Haurigot, M Garcia, S Marcó, A Ribera… - researchgate.net
Mucopolysaccharidosis type II (MPSII), or Hunter syndrome, is an X-linked recessive
lysosomal storage disease (LSD) caused by deficiency of iduronate-2-sulfatase (IDS)(1, 2) …
[HTML] jci.org

[HTML][HTML] CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)

S Motas, V Haurigot, M Garcia, S Marcó, A Ribera… - JCI …, 2016 - Am Soc Clin Investig
Mucopolysaccharidosis type II (MPSII), or Hunter syndrome, is an X-linked recessive
lysosomal storage disease (LSD) caused by deficiency of iduronate-2-sulfatase (IDS)(1, 2) …

CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)

S Motas, V Haurigot, M Garcia, S Marcó… - JCI …, 2016 - pubmed.ncbi.nlm.nih.gov
Mucopolysaccharidosis type II (MPSII) is an X-linked lysosomal storage disease
characterized by severe neurologic and somatic disease caused by deficiency of iduronate …
[PDF] academia.edu

[PDF][PDF] CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)

S Motas, V Haurigot, M Garcia, S Marcó, A Ribera… - academia.edu
Mucopolysaccharidosis type II (MPSII), or Hunter syndrome, is an X-linked recessive
lysosomal storage disease (LSD) caused by deficiency of iduronate-2-sulfatase (IDS)(1, 2) …

CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)

S Motas, V Haurigot, M Garcia, S Marcó, A Ribera… - JCI …, 2016 - portalrecerca.uab.cat
Mucopolysaccharidosis type II (MPSII) is an X-linked lysosomal storage disease
characterized by severe neurologic and somatic disease caused by deficiency of iduronate …

CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome).

S Motas, V Haurigot, M Garcia, S Marcó, A Ribera… - JCI Insight, 2016 - europepmc.org
Mucopolysaccharidosis type II (MPSII) is an X-linked lysosomal storage disease
characterized by severe neurologic and somatic disease caused by deficiency of iduronate …